WallStreetZenWallStreetZen

Sectors & IndustriesHealthcare
Best Healthcare Stocks to Buy Now (2024)
Top healthcare stocks in 2024 ranked by overall Zen Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

Sector: Healthcare
Ticker
Company
Zen Score
Valuation Score
Financials Score
Forecast Score
Performance Score
Dividends Score
PCRX
PACIRA BIOSCIENCES INC
67
100
71
56
40
CORT
CORCEPT THERAPEUTICS INC
67
71
71
56
70
INCY
INCYTE CORP
64
86
86
56
30
NBIX
NEUROCRINE BIOSCIENCES INC
64
43
86
67
60
MOH
MOLINA HEALTHCARE INC
64
43
86
56
70

Upgrade to Premium to View More

Use Zen Score to quickly analyze stock fundamentals, even if you don't have a finance background. We run time-tested due diligence checks inspired by legendary investors like Warren Buffett, and score each company based on how many they pass/fail.

Already have a premium account? Sign In

Healthcare Industries

IndustryStocks1d %1w %1m %1y %Zen ScoreP/E ratioP/B RatioROEROAROCEUpside/DownsideConsensus
680+0.73%-1.37%+1.10%-19.83%8.12x6.05x+18.58%+3.64%-28.41%+80.60%Strong Buy
66+1.86%+7.60%+9.41%+9.90%37.94x4.42x-13.06%+6.40%+11.34%+6.06%Buy
18+0.52%+0.76%+5.98%+15.71%31.30x6.36x+33.50%+8.08%+14.20%+11.91%Buy
88+0.55%-0.13%+6.18%-13.12%-2.86x2.16x+11.73%+3.90%+6.88%+33.30%Strong Buy
12-0.08%+1.59%+5.67%+3.70%25.10x3.02x+15.15%+4.73%+11.75%+13.30%Buy
56-0.07%-2.90%-2.42%-21.75%11.78x3.33x+6.87%+2.32%+5.85%+32.10%Buy
47+0.76%+1.55%+3.12%+11.96%40.51x4.58x-92.16%+6.58%+13.66%+14.04%Buy
155+1.29%-1.69%+0.61%-14.13%29.59x3.94x+7.14%+5.15%+8.26%+21.26%Buy
10-0.40%+0.03%+0.22%+26.25%26.34x105.24x-10.32%+3.42%+19.53%+10.81%Buy
52+1.88%+1.85%+4.72%-6.86%59.11x3.56x+11.29%+7.71%+10.06%+18.68%Buy

Healthcare Stocks FAQ

What are the best healthcare stocks to buy right now in May 2024?

According to Zen Score, the 3 best healthcare stocks to buy right now are:

1. Pacira Biosciences (NASDAQ:PCRX)


Pacira Biosciences (NASDAQ:PCRX) is the top healthcare stock with a Zen Score of 67, which is 43 points higher than the healthcare sector average of 24. It passed 21 out of 33 due diligence checks and has strong fundamentals. Pacira Biosciences has seen its stock lose -27.43% over the past year, underperforming other healthcare stocks by -21 percentage points.

Pacira Biosciences has an average 1 year price target of $46.71, an upside of 51.57% from Pacira Biosciences's current stock price of $30.82.

Pacira Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Pacira Biosciences, 28.57% have issued a Strong Buy rating, 71.43% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Corcept Therapeutics (NASDAQ:CORT)


Corcept Therapeutics (NASDAQ:CORT) is the second best healthcare stock with a Zen Score of 67, which is 43 points higher than the healthcare sector average of 24. It passed 22 out of 33 due diligence checks and has strong fundamentals. Corcept Therapeutics has seen its stock return 14.96% over the past year, overperforming other healthcare stocks by 22 percentage points.

Corcept Therapeutics has an average 1 year price target of $40.67, an upside of 47.02% from Corcept Therapeutics's current stock price of $27.66.

Corcept Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Corcept Therapeutics, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third best healthcare stock with a Zen Score of 64, which is 40 points higher than the healthcare sector average of 24. It passed 20 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -13.82% over the past year, underperforming other healthcare stocks by -7 percentage points.

Incyte has an average 1 year price target of $74.92, an upside of 31.33% from Incyte's current stock price of $57.05.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 30.77% have issued a Strong Buy rating, 23.08% have issued a Buy, 46.15% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the healthcare stocks with highest dividends?

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

1. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 55.38%, which is 53 percentage points higher than the healthcare sector average of 2.75%.

Mei Pharma's dividend payout ratio of 44.6% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 7.96%, which is 5 percentage points higher than the healthcare sector average of 2.75%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 82.1% indicates that its high dividend yield is sustainable for the long-term.

3. Siga Technologies (NASDAQ:SIGA)


Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 7.64%, which is 5 percentage points higher than the healthcare sector average of 2.75%.

Siga Technologies's dividend payout ratio of 95.5% indicates that its high dividend yield might not be sustainable for the long-term.

Why are healthcare stocks up?

Healthcare stocks were up 0.98% in the last day, and up 0.91% over the last week. Harrow was the among the top gainers in the healthcare sector, gaining 34.55% yesterday.

Harrow shares are trading higher after the company reported Q1 financial results.

What are the most undervalued healthcare stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued healthcare stocks right now are:

1. Inmode (NASDAQ:INMD)


Inmode (NASDAQ:INMD) is the most undervalued healthcare stock based on WallStreetZen's Valuation Score. Inmode has a valuation score of 100, which is 85 points higher than the healthcare sector average of 15. It passed 7 out of 7 valuation due diligence checks.

Inmode's stock has dropped -45.42% in the past year. It has underperformed other stocks in the healthcare sector by -39 percentage points.

2. Pacira Biosciences (NASDAQ:PCRX)


Pacira Biosciences (NASDAQ:PCRX) is the second most undervalued healthcare stock based on WallStreetZen's Valuation Score. Pacira Biosciences has a valuation score of 100, which is 85 points higher than the healthcare sector average of 15. It passed 7 out of 7 valuation due diligence checks.

Pacira Biosciences's stock has dropped -27.43% in the past year. It has underperformed other stocks in the healthcare sector by -21 percentage points.

3. Collegium Pharmaceutical (NASDAQ:COLL)


Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued healthcare stock based on WallStreetZen's Valuation Score. Collegium Pharmaceutical has a valuation score of 86, which is 71 points higher than the healthcare sector average of 15. It passed 6 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 41.66% in the past year. It has overperformed other stocks in the healthcare sector by 49 percentage points.

Are healthcare stocks a good buy now?

49.48% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 34.11% over the next year.

What is the average p/e ratio of the healthcare sector?

The average P/E ratio of the healthcare sector is 26.97x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.